Sage Therapeutics Inc (NASDAQ:SAGE)’s traded shares stood at 1.18 million during the last session, with the company’s beta value hitting 0.88. At the close of trading, the stock’s price was $5.10, to imply a decrease of -5.03% or -$0.27 in intraday trading. The SAGE share’s 52-week high remains $28.26, putting it -454.12% down since that peak but still an impressive -4.71% since price per share fell to its 52-week low of $5.34. The company has a valuation of $311.98M, with an average of 0.67 million shares in intraday trading volume over the past 10 days and average of 667.42K shares over the past 3 months.

Analysts have given a consensus recommendation of Hold for Sage Therapeutics Inc (SAGE), translating to a mean rating of 2.95. Of 8 analyst(s) looking at the stock, 1 analyst(s) give SAGE a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.44.

Sage Therapeutics Inc (NASDAQ:SAGE) trade information

After registering a -5.03% downside in the last session, Sage Therapeutics Inc (SAGE) has traded red over the past five days. The 5-day price performance for the stock is -19.18%, and -29.26% over 30 days. With these gigs, the year-to-date price performance is -76.47%. Short interest in Sage Therapeutics Inc (NASDAQ:SAGE) saw shorts transact 6.0 million shares and set a 8.29 days time to cover.

The extremes give us $9 and $105 for target low and target high price respectively. As such, SAGE has been trading -1958.82% off suggested target high and -76.47% from its likely low.

Sage Therapeutics Inc (SAGE) estimates and forecasts

Looking at statistics comparing Sage Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Sage Therapeutics Inc (SAGE) shares are -56.41% down over the last 6 months, with its year-to-date growth rate higher than industry average at 28.40% against 16.20%. Revenue is forecast to shrink -162.20% this quarter before jumping 28.80% for the next one. The rating firms project that company’s revenue will shrink -51.04% compared to the previous financial year.

Revenue forecast for the current quarter as set by 17 analysts is 14.15M. Meanwhile, for the current quarter, a total of 7 analyst(s) estimate revenue growth to 16.18M.Earnings reports from the last fiscal year show that sales brought in 77.97M and 7.9M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -81.86% before jumping 104.71% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.28% for the past 5-year period. While 2024 is set for a 28.43% return in earnings, projections for the next 5 years are at 16.80% annually.

SAGE Dividends

Sage Therapeutics Inc has its next earnings report out on 2025-Feb-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders

Sage Therapeutics Inc insiders hold 11.90% of total outstanding shares, with institutional holders owning 86.44% of the shares at 98.12% float percentage. In total, 86.44% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 6.42 million shares (or 10.6696% of shares), all amounting to roughly $69.68 million.

The next major institution holding the largest number of shares is FMR LLC with 5.82 million shares, or about 9.6836% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $63.24 million.